Ginkgo and Boehringer Ingelheim sign pact to mine microbes and find new molecules

Kyle LaHucik

Senior Reporter

Ginkgo Bioworks has lined up another biopharma partnership, allying with one of the largest privately held drug developers in a deal worth as much as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ginkgo and Boehringer Ingelheim sign pact to mine microbes and find new molecules

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Biotech industry worries over potential for RFK Jr. ally as FDA pick

GSK leaves biotech trade group BIO

Eisai slashes Leqembi sales forecast by almost $100M

New Trump era could be a boon for biopharma M&A, dealmaking

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Gink­go and Boehringer In­gel­heim sign pact to mine mi­crobes and find new mol­e­cules

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

GSK leaves biotech trade group BIO

Ei­sai slash­es Leqem­bi sales fore­cast by al­most $100M

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Ginkgo and Boehringer Ingelheim sign pact to mine microbes and find new molecules

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Eisai slashes Leqembi sales forecast by almost $100M

New Trump era could be a boon for biopharma M&A, dealmaking

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks